The online version of this article (doi:10.1186/s12958-017-0242-9) contains supplementary material, which is available to authorized users.
5α-reductase activity might be important during the development of polycystic ovary syndrome (PCOS). However, the changes of 5α-reductase activity in PCOS subjects and the relationship between 5α-reductase activity and body mass index (BMI), insulin resistance (IR) remain largely unknown.
We performed a meta-analysis to examine 5α-reductase activity in women with PCOS; exploratory subgroup analyses were also performed.
Five articles (with 356 cases and 236 controls) reporting 5α-reductase activity in patients with PCOS were selected for the meta-analysis. We observed significantly higher ratios of 5αTHF/THF (5α-reduced tetrahydrocortisol to 5β-reduced tetrahydrocortisol) and An/Et (androsteroneto/etiocholanolone) levels, which were used to assess 5α-reductase activity, among the patients with PCOS, [standardized mean differences (SMD) =0.43, 95%confidence intervals (95%CI) =0.25–0.61, P < 0.00001; SMD = 0.86, 95% CI = 0.29–1.44, P = 0.003]. We observed significant heterogeneity between studies for An/Et (I2 = 89% and P < 0.00001). According to the group analysis, women with PCOS exhibited increased 5α-reductase activity which was significantly associated with homeostasis model assessment of insulin resistance (HOMA-IR) regardless of obesity.
5α-reductase activity was enhanced in women with PCOS. Increased 5α-reductase activity in patients with PCOS was related to IR.
Additional file 1: Table S1. PRISMA 2009 Checklist. (DOC 70 kb)12958_2017_242_MOESM1_ESM.doc
Additional file 2: The search strategy and excluded studies with reasons. (DOCX 28 kb)12958_2017_242_MOESM2_ESM.docx
Additional file 3: Table S2. Data from the studies included in the meta-analysis. (DOCX 17 kb)12958_2017_242_MOESM3_ESM.docx
Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. Polycistic Ovary Syndr. 1992;4:377–84.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term healthiest related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25. CrossRef
O’Reilly MW, et al. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. J Clin Endocrinol Metab. 2014;99(3):1027–36.
Boda D, Paun D, Diaconeasa A. Evaluation of 5-alpha reductase activity on cultured fibroblast in patients with hyperandrogenemia. Rom J Intern Med. 2009;47(1):67–73. PubMed
Wells G, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ontario: Department of Epidemiology and Community Medicine, University of Ottawa; 2000.
Legro RS, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84(1):165–9. PubMed
- 5α-reductase activity in women with polycystic ovary syndrome: a systematic review and meta-analysis
- BioMed Central
Neu im Fachgebiet Gynäkologie und Geburtshilfe
Meistgelesene Bücher aus dem Fachgebiet
Mail Icon II